IXICO PLC
LSE:IXI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its Industry Average (0), the stock would be worth GBX-0.08 (101% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -1.5 | GBX6.88 |
0%
|
| Industry Average | 0 | GBX-0.08 |
-101%
|
| Country Average | 0 | GBX-0.17 |
-102%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
IXICO PLC
LSE:IXI
|
6.4m GBP | -1.5 | -3.9 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
936.1B USD | 1 841 | 3 881 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
178B USD | 31.8 | 26 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.6B USD | 26.2 | 34.3 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 105.4 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
331.7B CNY | 25.1 | 17.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
32.5B CHF | -165.5 | -119.8 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.7B USD | 34.5 | 25.3 | |
| US |
|
Waters Corp
NYSE:WAT
|
30.3B USD | 56.9 | 47.2 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
26.9B USD | 18.9 | 19.8 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26B USD | 33 | 29.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0.1 |
| Max | 1 344.9 |
Other Multiples
IXICO PLC
Glance View
IXICO Plc engages in the provision of technology-enabled specialty services to the global biopharmaceutical industry. The Company’s data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable trial design, site qualification, patient selection and clinical outcomes. The company provides technology-enabled services across all phases of clinical evaluation. The Company’s services include the collection, analysis, management and reporting of data generated during a clinical study and the outputs from the data analysis. The Company’s integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make better-informed decisions. Its geographical area includes Switzerland, United Kingdom, United States of America, Netherlands, Ireland and Europe.
